What is CytoMed Therapeutics Limited Ordinary Shares?
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 9.01M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.